Wechselwirkungen · Rasilez
Rasilez 150 mg film-coated tablets Rasilez 300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-208752 · Präparat HOS-154177
Furosemide and torasemide Oral co-administration of aliskiren and furosemide had no effect on the pharmacokinetics of aliskiren but reduced exposure to furosemide by 20-30% (the effect of aliskiren on furosemide administered intramuscularly or intravenously has not been investigated). After multiple doses of furosemide (60 mg/day) co-administered with aliskiren (300 mg/day) to patients with heart failure the urinary sodium excretion and the urine volume were reduced during the first 4 hours by 31% and 24%, respectively, as compared to furosemide alone. The mean weight of patients concomitantly treated with furosemide and 300 mg aliskiren (84.6 kg) was higher than the weight of patients treated with furosemide alone (83.4 kg). Smaller changes in furosemide pharmacokinetics and efficacy were observed with aliskiren 150 mg/day.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): furosemide (HOS-089060) sodium (HOS-109681)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-02T02:00:00Z · SHA-256 4518ee1f6936dd9da7c06dbb3fa8bed38b206400f5cb767391af486f27614e43 · Passage a0f1b39fb626d11c473def786be9d01e13c098b1257f564684cd77e69245a451 · Zeichen 4906–5742 im Abschnitt